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Abstract
BACKGROUND—Although screening of human immunodeficiency virus (HIV)-positive 
individuals for anal intraepithelial neoplasia (AIN; a precursor of anal cancer) has been practiced 
in San Francisco among HIV health care providers since the early 1990s, to the authors’ 
knowledge no study to date has focused on evaluating recent AIN trends.
METHODS—Cases of high-grade AIN 3 and invasive anal cancer from 2000 to 2009 were 
obtained from the San Francisco/Oakland Surveillance, Epidemiology, and End Results (SEER) 
population-based cancer registry. Age-standardized rates of AIN 3 and anal cancer were calculated 
overall and by demographic characteristics (sex, race, and age group). Log-linear regression 
calculated annual percent change in rates during 2000 to 2009, and rate ratios (RRs) and 95% 
confidence intervals (95% CIs), evaluated differences in rates during 2000 through 2004 and 2005 
through 2009.
RESULTS—During 2000 through 2009, the majority of AIN 3 cases occurred among men (1152 
of 1320 men; 87.3%). Rates of AIN 3 during the corresponding period increased by 11.48% per 
year (P <.05) among men and were stable among women. Comparing rates among men during 
2000 to 2004 with those during 2005 to 2009, the largest increases were noted among those aged 
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50 years to 64 years (RR, 2.47; 95% CI, 1.93–3.17) and among black individuals (RR, 3.49; 95% 
CI, 2.14–5.85). During the same period, anal cancer rates were stable among men and women.
CONCLUSIONS—Rates of AIN 3 increased in San Francisco during 2000 through 2009, in 
conjunction with an anal cytology screening program for high-risk groups, whereas rates of 
invasive anal cancer were unchanged. Continued surveillance is necessary to evaluate the impact 
of screening and human papillomavirus vaccination on the prevention of human papillomavirus-
related AIN and anal cancer.
Keywords
anal cancer; anal intraepithelial neoplasia; incidence; screening
INTRODUCTION
Anal cancer is biologically similar to cervical cancer, in that both are due to persistent 
infection of epithelial cells with oncogenic human papillomavirus (HPV) types (ie, 16/18) 
and are preceded by precursor lesions that may be detected with cytologic screening.1 The 
potential for high-grade anal intraepithelial neoplasia (the presumptive precursor lesion, AIN 
3, hereafter referred to as AIN) to progress to invasive anal cancer has been documented,2–4 
and immune suppression due to human immunodeficiency virus (HIV) infection is an 
important cofactor. Many studies have evaluated AIN and anal cancer among HIV-positive 
and HIV-negative men who have sex with men (MSM), who are at high risk for both 
outcomes.5–8 Furthermore, based on evidence provided in the current HIV treatment 
guidelines, AIN screening and treatment are considered to provide clinical benefits 
comparable to those of other opportunistic infection prevention measures among HIV-
positive individuals.9 In San Francisco County (an area with a high burden of HIV 
infection),10 cytologic screening (ie, anal Papanicolaou [Pap] testing) for AIN provided by 
many HIV health care practitioners to individuals with risk factors for anal cancer has been 
available since the early 1990s. Individuals with a previous HPV-related anogenital lesion or 
abnormal anal cytology are referred by primary care providers to the University of 
California at San Francisco Anal Neoplasia Clinic. Biopsy-confirmed high-grade AIN is 
treated to reduce the risk of progression to invasive anal cancer.11
In June 2012, the LAST (Lower Anogenital Squamous Terminology) Project consensus 
statement was issued by the College of American Pathologists and the American Society for 
Colposcopy and Cervical Pathology12 that standardized histopathologic terminology for 
AIN diagnosis by creating a 2-tiered nomenclature system (high-grade and low-grade) based 
on current knowledge of the biology of HPV-related lesions of the lower anogenital region 
and by providing consistent terminology among HPV-related lesions at different anogenital 
sites. Due to the high burden of anal cancer in San Francisco,13,14 the availability of AIN 
screening and treatment, and the recent focus on standardization of reporting, we used 
population-based cancer registry data to evaluate trends in high-grade AIN to inform 
diagnosis, reporting, and cancer control activities in the region, as well as to inform the 
potential future impact of the LAST recommendations.
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Data regarding cases of high-grade AIN (ie, AIN 3) and anal cancer diagnosed between 
2000 and 2009 were obtained from the San Francisco/Oakland area population-based cancer 
registry, which participates in the National Cancer Institute’s Surveillance, Epidemiology, 
and End Results (SEER) program. We focused on cases occurring between 2000 and 2009 
because this was the most recent 10-year period for which data were available and because 
AIN reporting was likely to have been stable during this period because the familiarity of 
health care workers with anal cancer screening increased and reporting became more 
routine. Consistent with previously established methodology, histologically confirmed cases 
of AIN and anal cancer were selected according to anatomic site and histology, using the 
third edition of the International Classification of Diseases for Oncology (ICD-O-3) site 
codes C21.0 (anus), C21.1 (anal canal), C20.9 (rectum), and 21.8 (overlapping lesion of the 
rectum, anus, and anal canal), and were restricted to squamous cell carcinoma (SCC; 
histology codes 8050–8084 and 8120–8131) because this subtype is associated with 
persistent HPV infection.15,16 Rectal cancers are typically adenocarcinomas, and rectal 
SCCs appearing in registry data are frequently misclassified cases of AIN and anal cancer, 
and therefore rectal SCCs were included in all analyses.17 Cases of AIN 3 were identified 
using the behavior code in situ to differentiate between invasive anal cancers, and both were 
classified by sex, age, and race. Cases were divided by the corresponding population 
denominators and expressed as rates per 100,000 population, and age-standardized to the 
2000 US standard population using SEER*Stat software.18
We evaluated temporal trends between 2000 and 2009 by fitting a weighted least squares 
regression model to the log-transformed annual age-standardized rates, weighted by the 
inverse of their variance.19 The annual percent change (APC) was considered to be 
statistically significant if the 2-sided P value for the parameter was <.05. To assess changes 
in rates by demographic characteristics, we calculated 5-year average rates for stability, and 
compared rates during 2000 to 2004 with those for 2005 through 2009 via the Poisson rate 
ratio (RR), with corresponding 95% confidence intervals (95% CIs).20
RESULTS
A total of 1319 diagnoses of high-grade AIN were identified in the San Francisco/Oakland 
cancer registry during 2000 through 2009. Table 1 shows the distribution of patients by 
demographic characteristics and calendar period. During 2000 through 2004 and 2005 
through 2009, most diagnoses were made among those aged 35 to 49 years and 50 to 64 
years and among those who were white. Greater than 85% of AIN 3 diagnoses occurred 
among males during both time periods.
Among men, overall high-grade AIN incidence rates increased by 11.48% per year between 
2000 and 2009 (P <.05) (Fig. 1). By calendar period, incidence rates nearly doubled from 
5.03 to 9.24 per 100,000 between the 2 time periods of 2000 through 2004 and 2005 through 
2009 (RR, 1.84; 95% CI, 1.62–2.08) (Table 2). Significant increases were also noted for 
men within each age stratum <65 years. Rates of high-grade AIN were found to significantly 
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increase among men of all races, with the largest increase noted between 2000 and 2004 and 
2005 and 2009 among black men (RR, 3.49; 95% CI, 2.14–5.85).
Among women, the overall incidence of high-grade AIN increased during 2000 through 
2009 by 3.88% per year, but this increase was not statistically significant (P =.31) (Fig. 1). 
By calendar period, rates increased from 0.85 to 1.19 per 100,000 between the 2 time 
periods of 2000 through 2004 and 2005 through 2009, respectively (RR, 1.40; 95% CI, 
1.02–1.94) (Table 2). Rates also increased nonsignificantly for women of every age group 
and race.
Overall, invasive anal cancer rates were found to be statistically stable for both men and 
women during 2000 through 2009 (Fig. 2), and there were no changes noted by 
demographic subgroups (Tables 3 and 4). By the end of this period, the year 2009, the 
incidence rate of AIN was 10-fold higher among men (12.5) versus women (1.3), whereas 
rates of invasive anal cancer were nearly the same (2.9 and 2.7, respectively, among men 
and women).
DISCUSSION
We observed significant increases in the population-based incidence rates of AIN 3 among 
men but not women in the San Francisco/Oakland cancer registry. These trends should be 
considered in the context of both the availability of screening and treatment for high-grade 
AIN and the high burden of invasive anal cancer among both men and women living in the 
San Francisco area.11,13,14,17 AIN 3 is reportable to cancer registries statewide in California 
and in other SEER program registry areas.21,22 However, strong collaborative efforts 
between cancer surveillance programs, clinicians conducting anal cytology screening, high-
resolution anoscopy (HRA) and HRA-guided biopsy and treatment of high-grade AIN, and 
pathologists involved with interpreting anal cytology and histology are needed to improve 
the accurate monitoring of AIN trends at the community level. Communication among these 
groups would promote the clinical care and management of patients with AIN, which might 
prevent many cases from progressing to invasive cancer. Routine screening of high-risk 
individuals would then also warrant evaluations at the broader population level. The 
increasing AIN 3 trends documented herein coincide with stable rates of anal cancer in the 
region. The impact of screening programs on invasive cancers and mortality outcomes is not 
known.
The current AIN incidence trends are likely to be the result of several factors, including the 
high incidence of HIV infection in the preceding 20 years and the focused nature of these 
infections among MSM (whom are also at high risk of HPV infections and anal 
neoplasia).5–8,23 Although HIV infection incidence and mortality have decreased over time, 
HIV prevalence has increased as a function of effective HIV therapies, thereby resulting in a 
large population at an increased risk of anal neoplasia in the region. To our knowledge, there 
are no data regarding trends in HPV infections occurring San Francisco, although anal HPV 
infections are detected in a very high percentage of HIV-infected adults.24 The elevated AIN 
3 rates among men compared with women reflect the excess of diagnoses among HIV-
positive men and higher relative rates of screening compared with women, regardless of 
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HIV status, in San Francisco. Screening of high-risk patients likely increased over time, 
although data are not available for a more systematic evaluation of contemporary screening 
rates.
The findings of the current study provide a baseline for monitoring the effect of increased 
screening, and potentially the future impact of HPV vaccination. Although HPV vaccination 
coverage levels remain low, they are increasing.25 Routine vaccination is recommended for 
girls and boys aged 11 years or 12 years.26–28 Vaccination is also recommended for 
unvaccinated females aged 13 years through 26 years and males aged 13 years through 21 
years. The vaccine is also recommended for gay and bisexual men (or any man who has sex 
with men) and men with compromised immune systems (including HIV) through age 26 
years.28 Vaccination should ideally occur before sexual debut. During 2011, approximately 
1.3% of males aged 13 years to 17 years had received the full recommended 3-dose series of 
the HPV vaccine.29 As coverage levels increase and vaccinated cohorts enter age groups in 
which AIN and anal cancer risks are highest, the effect of vaccination would be most likely 
to manifest first as declines in population-based rates of high-grade AIN.1,22
The characteristics of screening and treatment coupled with trends in AIN and anal cancer 
rates in the current study underscore the need for studies to assess anal cytology practices in 
other areas and evaluations of the impact of such screening on these outcomes. In 1999, 
Goldie et al found it to be both clinically effective and cost-effective to screen HIV-positive 
MSM with annual anal Pap smears,30 and a recent systematic review31 summarized AIN 
screening practices among HIV-positive individuals. To the best of our knowledge, no 
studies to date have evaluated the efficacy of screening to reduce mortality from anal 
cancer.14 A cohort study in San Francisco demonstrated that 38% of HIV-positive and 17% 
of HIV-negative MSM developed AIN during 4 years of follow-up.7 A more recent 
Canadian study found 37% of HIV-positive MSM developed AIN over 3 years.5 However, 
to the best of our knowledge, data regarding AIN risk for longer time periods are not yet 
available.8 Studies by de Pokomandy et al and Palefsky et al5,7 as well as others6,32 found 
HIV infection, age, nadir CD4-positive T-lymphocyte count, number of HPV infections and 
specific HPV types (ie, 16/18), and other characteristics were independent predictors of AIN 
risk among MSM, although risk factors among women, and more generally, among 
individuals without HIV infection or men who are not MSM, remain unclear. Additional 
research is also needed to determine rates of progression from high-grade AIN to invasive 
cancer and to determine the host characteristics and mechanistic pathways involved in anal 
carcinogenesis.
The largest increase in AIN 3 incidence rates during the 10-year study period was noted 
among black men and the reason for this strong increase is unclear. In part, the trend may 
reflect improved access to care (especially for black HIV-positive MSM who are now more 
engaged in the health care system due to focused HIV programs). However, it is interesting 
to note that AIN 3 rates during 2005 through 2009 were similar among black (11.18 per 
100,000 population) and white (10.12 per 100,000 population) men, underscoring the 
importance of interventions for all men at risk of developing AIN. Another recent study also 
found increases in the incidence of AIN 3 in San Francisco, although it did not provide a 
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detailed evaluation of trends by sex, race, and age groups and focused on different 
outcomes.33
The current evaluation of trends in AIN rates also should be considered in the context of the 
new LAST Project pathology recommendations.12 The recommendations provide guidance 
for pathologists diagnosing and clinicians screening for AIN, and are meant to promote the 
use of common terminology across disciplines using a 2-tiered nomenclature system that 
classifies AIN as either high grade or low grade. Importantly, to be reported to cancer 
surveillance programs, such diagnoses still need to be coded as AIN 3.21 The LAST Project 
statement also provides guidance for p16 (a cell regulatory protein) testing, which might be 
beneficial in improving the diagnostic accuracy of high-grade AIN. In terms of AIN 
treatment, the protocol used by many health care providers in San Francisco (mainly those 
treating HIV-positive patients) calls for abnormal cytology to be confirmed with biopsy via 
HRA and for those individuals with AIN 2 or AIN 3 to be treated (AIN 2 is a lower-grade 
lesion but some may progress to AIN 3 and eventually invasive cancer, and therefore they 
are also treated).34 Treatment can be challenging because of tolerability and side effects, and 
to the best of our knowledge only limited efficacy data exist. Modalities range from topical 
and ablative therapies to surgical excision for extensive disease.34 The optimal surveillance 
interval after treatment for recurrent lesions is unknown.
To our knowledge, this assessment of temporal trends in high-grade AIN using high-quality, 
population-based surveillance data are the first to provide detailed information focused 
solely on AIN 3 rates by sex, race, and age group in an area with an existing screening 
program. The current analysis also has limitations. We had no data available regarding HIV 
infection, although many of the AIN cases included in the current study were likely to have 
been HIV-positive based on previous studies of AIN and anal cancer in the region.13,17 In 
addition, although the cancer registry is population-based, the completeness of AIN 
reporting likely increased over time as screening became more widespread in San Francisco 
and clinician awareness of AIN grew, therefore complicating the interpretation of temporal 
trends.11 This issue may have been partly addressed by restricting our analysis to the most 
recent 10-year period for which there were available data. In addition, AIN is a rare outcome 
and this was evident in the analysis of incidence rates among women, for whom the APC 
analysis (of annual rates) revealed a nonsignificant increase likely due to a lack of statistical 
power (P =.31), but the RR analysis (of 5-year average annual rates) demonstrated a 
significant increase just below the decision threshold. In addition, we focused on the San 
Francisco area because of our prior knowledge of an AIN screening program and this 
selection limits the generalizability of our findings. Overall AIN 3 rates significantly 
increased in 4 other SEER 9 registries during the same time period (Connecticut, Detroit, 
Iowa, and Seattle; data not shown). The findings of the current study demonstrate the 
usefulness of cancer registry data for monitoring anal cancer precursor lesions at the 
population level.
The results of the current study demonstrated increases in the occurrence of AIN among 
men between 2000 and 2009 in the San Francisco/Oakland cancer registry. These increases 
occurred within the context of an AIN screening program that was focused mainly on HIV-
positive individuals, and coincided with stable incidence rates of invasive anal cancer. This 
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baseline evaluation of AIN rates provides data for the future monitoring of the effect of 
more widely disseminated screening and the delayed effect of increasing HPV vaccination 
coverage levels in the prevention of AIN and anal cancer.
Acknowledgments
FUNDING SUPPORT
No specific funding was disclosed.
References
1. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection 
and neoplasia. J Natl Cancer Inst Monogr. 2003; (31):14–19. [PubMed: 12807940] 
2. Kreuter A, Potthoff A, Brockmeyer NH, et al. Anal carcinoma in human immunodeficiency virus-
positive men: results of a prospective study from Germany. Br J Dermatol. 2010; 162:1269–1277. 
[PubMed: 20184584] 
3. Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial 
neoplasia. Br J Surg. 2005; 92:1133–1136. [PubMed: 16044425] 
4. Watson AJ, Smith BB, Whitehead MR, Sykes PH, Frizelle FA. Malignant progression of anal intra-
epithelial neoplasia. ANZ J Surg. 2006; 76:715–717. [PubMed: 16916390] 
5. de Pokomandy A, Rouleau D, Ghattas G, et al. HAART and progression to high-grade anal 
intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis. 
2011; 52:1174–1181. [PubMed: 21364075] 
6. Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active 
antiretroviral therapy era among HIV-positive men who have sex with men. AIDS. 2005; 19:1407–
1414. [PubMed: 16103772] 
7. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-
grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and 
bisexual men. AIDS. 1998; 12:495–503. [PubMed: 9543448] 
8. Severini A. Anal intraepithelial neoplasia in men living with HIV in the era of highly active 
antiretroviral therapy. Clin Infect Dis. 2011; 52:1182–1183. [PubMed: 21364076] 
9. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and 
treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from 
CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious 
Diseases Society of America. MMWR Recomm Rep. 2009; 58(RR-4):1–207. quiz CE1–CE4. 
10. [Accessed June 25, 2013] San Francisco Department of Public Health HIV/AIDS Epidemiology 
Annual Report. HIV Epidemiology Section. sfdph.org/dph/files/reports/RptsHIVAIDS/
AnnualReport2011.pdf
11. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High-resolution anoscopy targeted surgical 
destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon 
Rectum. 2008; 51:829–835. discussion 835–837. [PubMed: 18363070] 
12. Darragh TM, Colgan TJ, Cox JT, et al. Members of the LAST Project Work Groups. The Lower 
Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: 
background and consensus recommendations from the College of American Pathologists and the 
American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012; 
136:1266–1297. [PubMed: 22742517] 
13. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active 
antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 
2007; 165:1143–1153. [PubMed: 17344204] 
14. Katz KA, Clarke CA, Bernstein KT, Katz MH, Klausner JD. Is there a proven link between anal 
cancer screening and reduced morbidity or mortality? Ann Intern Med. 2009; 150:283–284. author 
reply 284–285. [PubMed: 19221387] 
Simard et al. Page 7













15. Watson M, Saraiya M, Ahmed F, et al. Using population-based cancer registry data to assess the 
burden of human papillomavirus-associated cancers in the United States: overview of methods. 
Cancer. 2008; 113(suppl 10):2841–2854. [PubMed: 18980203] 
16. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated 
anal cancers in the US. Cancer. 2008; 113(suppl 10):2892–2900. [PubMed: 18980293] 
17. Cress RD, Holly EA. Incidence of anal cancer in California: increased incidence among men in 
San Francisco, 1973–1999. Prev Med. 2003; 36:555–560. [PubMed: 12689800] 
18. Surveillance Research Program, National Cancer Institute. [Accessed June 25, 2013] SEER*-Stat 
software. Version 7.0.5. seer.cancer.gov/seerstat
19. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with 
applications to cancer rates. Stat Med. 2000; 19:335–351. [PubMed: 10649300] 
20. Rothman, J.; Greenland, S.; Lash, T. Modern Epidemiology. Philadelphia, PA: Lippincott 
Williams and Wilkins; 2008. 
21. Surveillance Systems Branch, Surveillance Research Program, Division of Cancer Control and 
Population Sciences, National Cancer Institute. [Accessed June 25, 2013] SEER Program Coding 
and Staging Manual. seer.cancer.gov/manuals/2011/SPCSM_2011_maindoc_09272011.pdf
22. Saraiya M, Goodman MT, Datta SD, Chen VW, Wingo PA. Cancer registries and monitoring the 
impact of prophylactic human papillomavirus vaccines: the potential role. Cancer. 2008; 113(suppl 
10):3047–3057. [PubMed: 18980287] 
23. Xia Q, Nonoyama A, Molitor F, Webb D, Osmond D. Recent decline in the incidence of human 
immunodeficiency virus infection among California men who have sex with men. Am J 
Epidemiol. 2011; 174:203–210. [PubMed: 21586631] 
24. Hernandez AL, Efird JT, Holly EA, Berry JM, Jay N, Palefsky JM. Risk factors for anal human 
papillomavirus infection type 16 among HIV-positive men who have sex with men in San 
Francisco. J Acquir Immune Defic Syndr. published online ahead of print April 22, 2013. 
25. Centers for Disease Control and Prevention (CDC). . National and state vaccination coverage 
among adolescents aged 13 through 17 years-United States, 2010. MMWR Morb Mortal Wkly 
Rep. 2011; 60:1117–1123. [PubMed: 21866084] 
26. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Centers for Disease 
Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). 
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2):1–24. [PubMed: 
17380109] 
27. Centers for Disease Control and Prevention (CDC). . FDA licensure of bivalent human 
papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination 
recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR 
Morb Mortal Wkly Rep. 2010; 59:626–629. [PubMed: 20508593] 
28. Centers for Disease Control and Prevention (CDC). . Recommendations on the use of quadrivalent 
human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 
2011. MMWR Morb Mortal Wkly Rep. 2011; 60:1705–1708. [PubMed: 22189893] 
29. Centers for Disease Control and Prevention (CDC). . National and state vaccination coverage 
among adolescents aged 13–17 years-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 
61:671–677. [PubMed: 22932301] 
30. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical 
effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in 
homosexual and bisexual HIV-positive men. JAMA. 1999; 281:1822–1829. [PubMed: 10340370] 
31. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals 
for anal cancer precursor lesions: a systematic review. Clin Infect Dis. 2006; 43:223–233. 
[PubMed: 16779751] 
32. Salit IE, Tinmouth J, Chong S, et al. Screening for HIV-associated anal cancer: correlation of HPV 
genotypes, p16, and E6 transcripts with anal pathology. Cancer Epidemiol Biomarkers Prev. 2009; 
18:1986–1992. [PubMed: 19567510] 
Simard et al. Page 8













33. Amirian ES, Fickey PA Jr, Scheurer ME, Chiao EY. Anal cancer incidence and survival: 
comparing the greater San-Francisco bay area to other SEER cancer registries. PLoS One. 2013; 
8:e58919. [PubMed: 23484057] 
34. Park IU, Palefsky JM. Evaluation and management of anal intraepithelial neoplasia in HIV-
negative and HIV-positive men who have sex with men. Curr Infect Dis Rep. 2010; 12:126–133. 
[PubMed: 20461117] 
Simard et al. Page 9














Temporal trends in age-adjusted incidence rates of anal intraepithelial neoplasia 3 are shown 
for 466 men and 853 women in the San Francisco/Oakland Cancer Registry between 2000 
and 2009. APC indicates annual percent change. Triangles represent observed rates and the 
solid line represents the modeled rates based on log-linear regression. The asterisk indicates 
P <.05.
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Temporal trends in age-adjusted incidence rates of anal cancer are shown for 417 men and 
378 women in the San Francisco/Oakland Cancer Registry between 2000 and 2009. APC 
indicates annual percent change. Triangles represent observed rates and the solid line 
represents the modeled rates based on log-linear regression. The asterisk indicates P <.05.
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TABLE 1







Age, y, no. (%)
 20–34 46 (9.87) 102 (11.96)
 35–49 291 (62.45) 424 (49.71)
 50–64 112 (24.03) 291 (34.11)
 ≥65 17 (3.65) 36 (4.22)
Sex, no. (%)
 Male 398 (85.41) 753 (88.28)
 Female 68 (14.59) 100 (11.72)
Race, no. (%)
 White 373 (80.04) 634 (74.33)
 Black 37 (7.94) 95 (11.14)
 Other/unknown 56 (12.02) 124 (14.54)
Abbreviation: AIN 3, anal intraepithelial neoplasia 3.
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TABLE 2
Age-Adjusted Incidence Rates of AIN 3 in the San Francisco/Oakland Cancer Registry by Sex, Age Group, 
Race, and Calendar Period
Characteristic
Rate per 100,000 Population
RR (95% CI) P2000–2004 2005–2009
Overall 2.95 5.24 1.78 (1.59–2.00) <.001
Males 5.03 9.24 1.84 (1.62–2.08) <.001
Age, y
 20–34 1.57 3.77 2.41 (1.63–3.59) <.001
 35–49 9.96 15.24 1.53 (1.30–1.80) <.001
 50–64 5.40 13.33 2.47 (1.93–3.17) <.001
 ≥65 0.95 1.97 2.08 (0.94–4.91) .073
Race
 White 5.95 10.12 1.70 (1.48–1.96) <.001
 Black 3.20 11.18 3.49 (2.14–5.85) <.001
 Other/unknown 2.78 5.90 2.13 (1.49–3.06) <.001
Females 0.85 1.19 1.40 (1.02–1.94) .038
 Age, y
 20–34 0.24 0.57 2.37 (0.83–7.63) .123
 35–44 1.34 1.41 1.05 (0.63–1.73) .937
 50–64 1.19 1.91 1.60 (0.92–2.87) .102
 ≥65 0.50 0.92 1.84 (0.68–5.48) .273
Race
 White 0.86 1.24 1.45 (0.98–2.16) .067
 Black 1.77 2.26 1.28 (0.60–2.80) .611
 Other/unknown 0.42 0.66 1.57 (0.61–4.34) .428
Abbreviation: 95% CI, 95% confidence interval; AIN 3, anal intraepithelial neoplasia 3; RR, rate ratio.













Simard et al. Page 14
TABLE 3





 Male 206 (53.8) 211 (51.2)
 Female 177 (46.2) 201 (48.8)
Race, no. (%)
 White 320 (83.6) 341 (82.8)
 Black 46 (12.0) 48 (11.7)
 Other/unknown 17 (4.4) 23 (5.5)
a
Age-specific information is not displayed due to small cell counts.
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TABLE 4
Age-Adjusted Incidence Rates of Invasive Anal Cancer in the San Francisco/Oakland Cancer Registry by Sex, 
Age Group, Race, and Calendar Period
Rate per 100,000 Population
Characteristic 2000–2004 2005–2009 RR (95% CI) P
Overall 2.51 2.50 1.00 (0.86–1.15) .97
Males 2.88 2.72 0.95 (0.77–1.15) .60
Age, y
 20–34 a a
 35–49 2.52 2.36 0.94 (0.65–1.35) .78
 50–64 4.98 4.91 0.99 (0.73–1.37) .73
 ≥65 5.34 5.00 0.94 (0.63–1.40) .81
Race
 White 3.38 3.27 0.97 (0.78–1.20) .81
 Black 4.27 3.52 0.82 (0.45–1.50) .60
 Other/unknown a a
Females 2.16 2.26 1.04 (0.85–1.29) .71
Age, y
 20–34 a a
 35–44 1.44 1.00 0.70 (0.40–1.19) .20
 50–64 4.17 4.27 1.02 (0.74–1.42) .95
 ≥65 4.58 5.83 1.28 (0.91–1.78) .16
Race
 White 2.71 2.79 1.03 (0.82–1.30) .85
 Black 2.28 2.82 1.24 (0.63–2.44) .61
 Other/unknown a a
Abbreviation: 95% CI, 95% confidence interval; RR, rate ratio.
a
Data are not shown for rates based on fewer than 16 cases.
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